Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient With Stage III RenalCell Carcinoma. jkcvhl 2026, 13 (2), 21-28. https://doi.org/10.15586/jkcvhl.v13i2.455.